Analyst Price Target is $25.38
▲ +275.93% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Mind Medicine (MindMed) in the last 3 months. The average price target is $25.38, with a high forecast of $55.00 and a low forecast of $9.00. The average price target represents a 275.93% upside from the last price of $6.75.
Current Consensus is
Buy
The current consensus among 12 investment analysts is to buy stock in Mind Medicine (MindMed). This Buy consensus rating has held steady for over two years.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Read More